Details of the Drug

General Information of Drug (ID: DMQIA5K)

Drug Name

AT-1501

Indication

Disease Entry	ICD 11	Status	REF
Amyotrophic lateral sclerosis	8B60.0	Phase 2	[1]

Drug Type

Antibody

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
CD40L receptor (CD40)	TTN6Y9A	TNR5_HUMAN	Inhibitor	[1]

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Amyotrophic lateral sclerosis

ICD Disease Classification

8B60.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
CD40L receptor (CD40)	DTT	CD40	4.61E-01	0.56	0.5

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04322149) A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS. U.S.National Institutes of Health.